Table 1.
Clinicopathological characteristics of 80 invasive breast cancer patients
| Characteristics | pBRE I-II Survivors ≥8years (n = 21) | pBRE III Survivors ≥8years (n = 19) | pBRE I-II Survivors < 8 years (n = 20) | pBRE III Survivors <8 years (n = 20) |
|---|---|---|---|---|
|
Mean age (y) |
58 (39–72) |
52 (27–7) |
55 (39–71) |
53 (33–72) |
|
Histologic type |
|
|
|
|
| Ductal |
15 (71) |
18 (95) |
15 (75) |
16 (80) |
| Lobular |
2 (10) |
1 (5) |
4 (20) |
3 (15) |
| Ductal + lobular |
0 (0) |
0 (0) |
1 (5) |
0 (0) |
| Other |
3 (14) |
0 (0) |
0 (0) |
1 (5) |
| Not available |
1 (5) |
0 (0) |
0 (0) |
0 (0) |
|
Pathologic tumor size (mm) |
|
|
|
|
| pT1 (0–20) |
2 (9) |
6 (32) |
3 (15) |
5 (25) |
| pT2 (>20-50) |
18 (86) |
9 (47) |
16 (80) |
13 (65) |
| pT3 (>50) |
1 (5) |
4 (21) |
1 (5) |
2 (10) |
| pT4 |
0 (0) |
0 (0) |
0 (0) |
0 (0) |
|
BRE grade |
|
|
|
|
| I-II |
21 (100) |
|
20 (100) |
|
| III |
|
19 (100) |
|
20 (100) |
|
No. of axillary lymph nodes |
|
|
|
|
| 0 |
7 (33) |
7 (37) |
7 (35) |
7 (35) |
| 1-3 |
5 (24) |
7 (37) |
6 (30) |
6 (30) |
| ≥4 |
9 (43) |
5 (26) |
7 (35) |
7 (35) |
|
Surgery |
|
|
|
|
| Lumpectomy |
9 (43) |
6 (32) |
9 (45) |
6 (30) |
| Mastectomy |
12 (57) |
13 (68) |
11 (55) |
14 (70) |
|
ER/PR status |
|
|
|
|
| Negative |
11 (52) |
8 (42) |
13 (65) |
7 (35) |
| Positive |
9 (43) |
11 (58) |
7 (35) |
13 (65) |
| Not available |
1 (5) |
|
|
|
|
HER2/neu status |
|
|
|
|
| Positive |
7 (33) |
8 (42) |
8 (40) |
3 (15) |
| Negative |
11 (52) |
10 (53) |
11 (55) |
9 (45) |
| Not available | 3 (15) | 1 (5) | 1 (5) | 8 (40) |
(N) = No. of patients (%).
BRE, Bloom, Richardson, Elston/Ellis; ER/PR: Estrogen/progesterone receptor.